MedCo's PCSK9 challenger presents strong data

Pivotal phase 3 data for The Medicines Company’s longer-lasting PCSK9 cholesterol fighter shows the drug is at least as safe and effective as its two marketed rivals - Amgen's Repatha and Sanofi and Regeneron's Praluent.

In a 1,617-patient study, inclisiran cut bad cholesterol by 54% when added to statin therapy, a number comparable to the 50%-plus stats put up by existing PCSK9 inhibitors.

Click here to read the entire article.